Osteoporosis Screening

Bone density testing (also known as bone mass measurement) can predict a woman's risk for bone fractures, one of the most common and debilitating consequences of osteoporosis. (1) Medicare pays for bone density testing for five high-risk groups. (2) States can help most women not on Medicare gain access to this screening by requiring private insurers to cover bone density testing for high-risk people.

  • Osteoporosis Screening

      Strength Of Policy 2007 Change From 2004
    ALABAMA No/Harmful Policy Same
    ALASKA No/Harmful Policy Same
    ARIZONA No/Harmful Policy Same
    ARKANSAS No/Harmful Policy Same
    CALIFORNIA Meets Policy Better
    COLORADO No/Harmful Policy Same
    CONNECTICUT No/Harmful Policy Same
    DELAWARE No/Harmful Policy Same
    DISTRICT OF COLUMBIA No/Harmful Policy Same
    FLORIDA Meets Policy Same
    GEORGIA Weak Policy Same
    HAWAII No/Harmful Policy Same
    IDAHO No/Harmful Policy Same
    ILLINOIS Meets Policy Better
    INDIANA No/Harmful Policy Same
    IOWA No/Harmful Policy Same
    KANSAS Meets Policy Same
    KENTUCKY Meets Policy Better
    LOUISIANA Limited Policy Same
    MAINE No/Harmful Policy Same
    MARYLAND Meets Policy Same
    MASSACHUSETTS No/Harmful Policy Same
    MICHIGAN No/Harmful Policy Same
    MINNESOTA No/Harmful Policy Same
    MISSISSIPPI No/Harmful Policy Same
    MISSOURI Meets Policy Same
    MONTANA No/Harmful Policy Same
    NEBRASKA No/Harmful Policy Same
    NEVADA No/Harmful Policy Same
    NEW HAMPSHIRE No/Harmful Policy Same
    NEW JERSEY No/Harmful Policy Same
    NEW MEXICO No/Harmful Policy Same
    NEW YORK Meets Policy Same
    NORTH CAROLINA Meets Policy Same
    NORTH DAKOTA No/Harmful Policy Same
    OHIO No/Harmful Policy Same
    OKLAHOMA Meets Policy Same
    OREGON No/Harmful Policy Same
    PENNSYLVANIA No/Harmful Policy Same
    RHODE ISLAND No/Harmful Policy Same
    SOUTH CAROLINA No/Harmful Policy Same
    SOUTH DAKOTA No/Harmful Policy Same
    TENNESSEE Weak Policy Better
    TEXAS Meets Policy Same
    UTAH No/Harmful Policy Same
    VERMONT No/Harmful Policy Same
    VIRGINIA No/Harmful Policy Same
    WASHINGTON No/Harmful Policy Same
    WEST VIRGINIA No/Harmful Policy Same
    WISCONSIN No/Harmful Policy Same
    WYOMING No/Harmful Policy Same
     
    Meets PolicyMeets Policy 11  
    Limited PolicyLimited Policy 1  
    Weak PolicyWeak Policy 2  
    No/Harmful PolicyNo/Harmful Policy 37  
    Better Better 4  
    Worse Worse 0  
    Same Same 47  

    Does the state require private insurers to cover bone density screening for certain high-risk groups?

    States receive a "meets policy" if they require private insurers to cover bone density screening for people in all five high-risk categories.  States receive a "limited policy" if they require private insurers to cover bone density screening for any three of the five categories.  States receive a "weak policy" if they only require insurers to offer coverage of bone density screenings as a benefit in employer-sponsored insurance plans, but have not required that it be a mandated benefit in all of these insurance plans. States with no mandated bone density screening coverage requirements receive a "no policy."

    Data Source: Osteoporosis Screening, 2006.

    The Henry J. Kaiser Family Foundation, "State Mandated Benefits: Osteoporosis Screening, 2006," available at http://www.statehealthfacts.org/comparetable.jsp?cat=10&ind=491, accessed March 30, 3007.

1. For more information on osteoporosis, please see Department of Health and Human Services, Bone Health and Osteoporosis, A Report of the Surgeon General (2004), available at http://www.surgeongeneral.gov/library/bonehealth/content.html.

2. Medicare covers bone density testing (using all FDA-approved technologies) for five categories of high-risk individuals: estrogen-deficient women at clinical risk of osteoporosis and who are considering treatment; individuals with vertebral abnormalities; individuals receiving long-term glucocorticoid (steroid) therapy; individuals with primary hyperparathyroidism; and individuals being monitored to assess the response to or the efficacy of approved osteoporosis drug therapies. 42 U.S.C. § 1395x.